Precision medicine in pediatric cancer treatment скачать в хорошем качестве

Precision medicine in pediatric cancer treatment

Francois Doz, MD, Institut Curie, Paris, France, emphasizes the potential of precision medicine in pediatric cancers, particularly in cases like the the Phase I/II iMATRIX Alectinib trial (NCT04774718) of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors. However, he notes that the main barrier to its adoption is the need for comprehensive molecular documentation at diagnosis, including sequencing and genome sequencing, to enable rapid treatment adjustments. This is further complicated by the need for timely access to treatment results through clinical trials to ensure efficacy and safety. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.